FibroGen Historical Balance Sheet

FGEN Stock

USD 1.04 0.02 1.96%

Trend analysis of FibroGen balance sheet accounts such as Other Current Liabilities of 86.8 M or Total Current Liabilities of 128.8 M provides information on FibroGen's total assets, liabilities, and equity, which is the actual value of FibroGen to its prevalent stockholders. By breaking down trends over time using FibroGen balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining FibroGen latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether FibroGen is a good buy for the upcoming year.

FibroGen Inventory

43.64 Million

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.

To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.

About FibroGen Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of FibroGen at a specified time, usually calculated after every quarter, six months, or one year. FibroGen Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of FibroGen and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which FibroGen currently owns. An asset can also be divided into two categories, current and non-current.

FibroGen Balance Sheet Chart

FibroGen Balance Sheet is one of the main financial statements that report all assets, liabilities, and shareholders' equity for the current year. It provides a basis for different types of computing rates of return, such as return on equity (ROE) or return on asset (ROA), as well as shows how FibroGen uses and utilizes its capital. It also shows what exactly a company owns and owes.

At this time, FibroGen's Short Term Investments are very stable compared to the past year. As of the 29th of April 2024, Liabilities And Stockholders Equity is likely to grow to about 665.2 M, while Short and Long Term Debt Total is likely to drop about 103.2 M.

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of FibroGen assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in FibroGen books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on FibroGen balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of FibroGen are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from FibroGen's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into FibroGen current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in income.

To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.At this time, FibroGen's Short Term Investments are very stable compared to the past year. As of the 29th of April 2024, Liabilities And Stockholders Equity is likely to grow to about 665.2 M, while Short and Long Term Debt Total is likely to drop about 103.2 M.

	2021	2022	2023	2024 (projected)
Short and Long Term Debt Total	99.7M	89.9M	170.5M	103.2M
Total Assets	773.8M	610.1M	423.5M	665.2M

Short Long Term Debt Total Total Assets

FibroGen balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross
Total Assets		-0.37	0.35	0.45	0.64	0.6	-0.36	0.35	-0.59	-0.4	0.44	0.6	-0.23	0.23	0.32	-0.7	0.96	0.52	0.78	0.65	0.64	0.54	0.34	0.76	0.51	-0.34
Short Long Term Debt Total	-0.37		0.14	0.16	-0.61	0.23	0.21	0.45	0.48	-0.33	-0.03	-0.37	0.06	-0.47	-0.72	0.1	-0.36	0.02	0.07	0.02	-0.08	0.38	-0.35	0.04	0.28	0.96
Other Current Liab	0.35	0.14		0.96	-0.27	0.85	-0.6	0.53	-0.02	-0.84	0.91	0.05	-0.37	-0.45	0.03	-0.02	0.33	0.38	0.68	0.72	0.42	0.8	0.09	0.76	0.91	0.12
Total Current Liabilities	0.45	0.16	0.96		-0.22	0.93	-0.58	0.65	-0.16	-0.88	0.95	0.2	-0.36	-0.4	0.05	-0.15	0.45	0.34	0.8	0.79	0.39	0.9	0.03	0.85	0.98	0.13
Total Stockholder Equity	0.64	-0.61	-0.27	-0.22		-0.06	0.11	-0.16	-0.61	0.41	-0.16	0.54	0.08	0.6	0.52	-0.48	0.62	0.22	0.2	0.06	0.32	-0.16	0.32	0.14	-0.19	-0.57
Other Liab	0.6	0.23	0.85	0.93	-0.06		-0.6	0.64	-0.25	-0.87	0.81	0.31	-0.45	-0.34	0.01	-0.36	0.61	0.5	0.93	0.86	0.49	0.97	0.16	0.95	0.97	0.26
Property Plant And Equipment Net	-0.36	0.21	-0.6	-0.58	0.11	-0.6		0.04	0.29	0.67	-0.58	-0.3	0.73	0.44	-0.38	0.16	-0.42	-0.47	-0.55	-0.66	-0.18	-0.44	-0.41	-0.63	-0.52	0.05
Current Deferred Revenue	0.35	0.45	0.53	0.65	-0.16	0.64	0.04		0.0	-0.57	0.6	0.07	0.13	-0.29	-0.18	-0.27	0.3	0.36	0.63	0.44	0.33	0.78	-0.41	0.56	0.73	0.34
Net Debt	-0.59	0.48	-0.02	-0.16	-0.61	-0.25	0.29	0.0		0.01	-0.27	-0.99	0.36	-0.09	-0.76	0.26	-0.71	-0.08	-0.39	-0.26	0.16	-0.11	0.06	-0.37	-0.14	0.42
Retained Earnings	-0.4	-0.33	-0.84	-0.88	0.41	-0.87	0.67	-0.57	0.01		-0.78	-0.09	0.48	0.53	0.17	0.24	-0.41	-0.43	-0.74	-0.79	-0.39	-0.88	-0.09	-0.81	-0.9	-0.34
Accounts Payable	0.44	-0.03	0.91	0.95	-0.16	0.81	-0.58	0.6	-0.27	-0.78		0.29	-0.33	-0.45	0.27	-0.05	0.45	0.32	0.7	0.75	0.28	0.77	-0.12	0.78	0.88	-0.07
Cash	0.6	-0.37	0.05	0.2	0.54	0.31	-0.3	0.07	-0.99	-0.09	0.29		-0.39	0.01	0.69	-0.28	0.72	0.09	0.44	0.29	-0.18	0.18	-0.11	0.4	0.19	-0.31
Non Current Assets Total	-0.23	0.06	-0.37	-0.36	0.08	-0.45	0.73	0.13	0.36	0.48	-0.33	-0.39		0.46	-0.28	0.13	-0.43	-0.42	-0.33	-0.54	-0.11	-0.32	-0.15	-0.48	-0.35	-0.06
Non Currrent Assets Other	0.23	-0.47	-0.45	-0.4	0.6	-0.34	0.44	-0.29	-0.09	0.53	-0.45	0.01	0.46		-0.05	-0.34	0.11	-0.38	-0.14	-0.29	0.19	-0.34	0.5	-0.23	-0.38	-0.52
Other Assets	0.32	-0.72	0.03	0.05	0.52	0.01	-0.38	-0.18	-0.76	0.17	0.27	0.69	-0.28	-0.05		0.04	0.41	0.2	0.13	0.11	-0.2	-0.16	-0.06	0.13	-0.06	-0.63
Long Term Debt	-0.7	0.1	-0.02	-0.15	-0.48	-0.36	0.16	-0.27	0.26	0.24	-0.05	-0.28	0.13	-0.34	0.04		-0.65	-0.44	-0.54	-0.5	-0.57	-0.36	-0.42	-0.54	-0.26	0.05
Cash And Short Term Investments	0.96	-0.36	0.33	0.45	0.62	0.61	-0.42	0.3	-0.71	-0.41	0.45	0.72	-0.43	0.11	0.41	-0.65		0.53	0.76	0.67	0.54	0.53	0.24	0.77	0.5	-0.32
Net Receivables	0.52	0.02	0.38	0.34	0.22	0.5	-0.47	0.36	-0.08	-0.43	0.32	0.09	-0.42	-0.38	0.2	-0.44	0.53		0.55	0.57	0.64	0.46	0.15	0.57	0.41	0.13
Common Stock Total Equity	0.78	0.07	0.68	0.8	0.2	0.93	-0.55	0.63	-0.39	-0.74	0.7	0.44	-0.33	-0.14	0.13	-0.54	0.76	0.55		0.79	0.55	0.9	0.24	0.94	0.87	0.11
Common Stock Shares Outstanding	0.65	0.02	0.72	0.79	0.06	0.86	-0.66	0.44	-0.26	-0.79	0.75	0.29	-0.54	-0.29	0.11	-0.5	0.67	0.57	0.79		0.59	0.81	0.25	0.95	0.82	0.05
Short Term Investments	0.64	-0.08	0.42	0.39	0.32	0.49	-0.18	0.33	0.16	-0.39	0.28	-0.18	-0.11	0.19	-0.2	-0.57	0.54	0.64	0.55	0.59		0.51	0.49	0.59	0.46	-0.1
Non Current Liabilities Total	0.54	0.38	0.8	0.9	-0.16	0.97	-0.44	0.78	-0.11	-0.88	0.77	0.18	-0.32	-0.34	-0.16	-0.36	0.53	0.46	0.9	0.81	0.51		0.04	0.9	0.97	0.36
Other Current Assets	0.34	-0.35	0.09	0.03	0.32	0.16	-0.41	-0.41	0.06	-0.09	-0.12	-0.11	-0.15	0.5	-0.06	-0.42	0.24	0.15	0.24	0.25	0.49	0.04		0.25	0.03	-0.23
Other Stockholder Equity	0.76	0.04	0.76	0.85	0.14	0.95	-0.63	0.56	-0.37	-0.81	0.78	0.4	-0.48	-0.23	0.13	-0.54	0.77	0.57	0.94	0.95	0.59	0.9	0.25		0.9	0.07
Total Liab	0.51	0.28	0.91	0.98	-0.19	0.97	-0.52	0.73	-0.14	-0.9	0.88	0.19	-0.35	-0.38	-0.06	-0.26	0.5	0.41	0.87	0.82	0.46	0.97	0.03	0.9		0.25
Property Plant And Equipment Gross	-0.34	0.96	0.12	0.13	-0.57	0.26	0.05	0.34	0.42	-0.34	-0.07	-0.31	-0.06	-0.52	-0.63	0.05	-0.32	0.13	0.11	0.05	-0.1	0.36	-0.23	0.07	0.25

Click cells to compare fundamentals

FibroGen Account Relationship Matchups

FibroGen balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	857.4M	826.8M	773.8M	610.1M	423.5M	665.2M
Short Long Term Debt Total	51.1M	37.7M	99.7M	89.9M	170.5M	103.2M
Other Current Liab	83.8M	119.5M	172.6M	219.4M	172.9M	86.8M
Total Current Liabilities	102.7M	163.2M	225.5M	273.6M	217.7M	128.8M
Total Stockholder Equity	516.1M	422.2M	209.1M	(21.4M)	(204.2M)	(194.0M)
Other Liab	162.8M	178.1M	212.8M	241.4M	277.6M	147.1M
Property Plant And Equipment Net	82.3M	63.3M	120.2M	100.5M	81.4M	89.5M
Current Deferred Revenue	490K	6.5M	15.9M	13.1M	12.7M	10.0M
Net Debt	(75.2M)	(640.7M)	(71.5M)	(65.8M)	56.8M	59.6M
Retained Earnings	(784.7M)	(974.0M)	(1.3B)	(1.6B)	(1.8B)	(1.7B)
Accounts Payable	6.1M	24.8M	26.1M	30.8M	18.0M	13.0M
Cash	126.3M	678.4M	171.2M	155.7M	113.7M	108.0M
Non Current Assets Total	154.9M	71.7M	299.8M	117.3M	92.0M	146.7M
Non Currrent Assets Other	11.4M	5.5M	8.0M	7.4M	3.6M	6.4M
Other Assets	9.5M	38.1M	8.0M	6.9M	1.0	0.95
Long Term Debt	17.2M	16.8M	16.8M	71.9M	64.7M	46.3M
Cash And Short Term Investments	533.8M	686.5M	405.2M	422.0M	235.6M	404.9M
Net Receivables	28.5M	41.9M	17.4M	16.3M	41.1M	25.9M
Common Stock Total Equity	854K	877K	914K	929K	1.1M	716.1K
Common Stock Shares Outstanding	86.6M	89.9M	92.3M	93.6M	97.3M	78.2M
Short Term Investments	407.5M	8.1M	234.0M	266.3M	121.9M	165.1M
Liabilities And Stockholders Equity	857.4M	826.8M	773.8M	610.1M	423.5M	665.2M
Non Current Liabilities Total	219.2M	222.2M	319.2M	338.0M	368.1M	261.8M
Other Current Assets	133.4M	1.8M	5.1M	4.4M	13.4M	17.1M
Other Stockholder Equity	1.3B	1.4B	1.5B	1.5B	1.6B	1.0B
Total Liab	322.0M	385.4M	544.7M	611.6M	585.7M	390.6M
Property Plant And Equipment Gross	82.3M	63.3M	120.2M	100.5M	253.1M	138.8M
Total Current Assets	702.5M	755.1M	474.1M	492.8M	331.6M	463.5M
Accumulated Other Comprehensive Income	(747K)	(4.5M)	(4.2M)	(5.7M)	(6.9M)	(6.5M)
Short Term Debt	12.4M	12.3M	11.0M	10.3M	14.1M	19.1M
Common Stock	877K	914K	929K	942K	988K	773.7K
Property Plant Equipment	42.7M	33.6M	120.2M	100.9M	90.8M	86.7M
Net Tangible Assets	516.1M	422.2M	209.1M	(21.4M)	(19.3M)	(18.3M)
Long Term Investments	61.1M	244K	171.6M	9.4M	5.3M	5.0M
Retained Earnings Total Equity	(715.8M)	(784.7M)	(974.0M)	(1.3B)	(1.1B)	(1.2B)
Capital Surpluse	1.2B	1.3B	1.4B	1.5B	1.7B	1.2B

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

When determining whether FibroGen offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of FibroGen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Fibrogen Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Fibrogen Stock:

How To Invest In FibroGen

Details

Is FibroGen Stock a good investment?

Details

What is FibroGen's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.

Note that the FibroGen information on this page should be used as a complementary analysis to other FibroGen's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.

Complementary Tools for FibroGen Stock analysis

When running FibroGen's price analysis, check to measure FibroGen's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy FibroGen is operating at the current time. Most of FibroGen's value examination focuses on studying past and present price action to predict the probability of FibroGen's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move FibroGen's price. Additionally, you may evaluate how the addition of FibroGen to your portfolios can decrease your overall portfolio volatility.

	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years
	Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments
	Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk
	Bonds Directory Find actively traded corporate debentures issued by US companies
	Stocks Directory Find actively traded stocks across global markets
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios

Is FibroGen's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroGen. If investors know FibroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

0.536

Earnings Share

(2.92)

Revenue Per Share

1.518

Quarterly Revenue Growth

(0.21)

Return On Assets

(0.36)

The market value of FibroGen is measured differently than its book value, which is the value of FibroGen that is recorded on the company's balance sheet. Investors also form their own opinion of FibroGen's value that differs from its market value or its book value, called intrinsic value, which is FibroGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroGen's market value can be influenced by many factors that don't directly affect FibroGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between FibroGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

FibroGen Historical Balance Sheet

FibroGen Inventory

43.64 Million

About FibroGen Balance Sheet Analysis

FibroGen Balance Sheet Chart

Total Assets

Total Current Liabilities

FibroGen balance sheet Correlations

FibroGen Account Relationship Matchups

High Positive Relationship

High Negative Relationship

FibroGen balance sheet Accounts

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

Complementary Tools for FibroGen Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Liab	+ 0.98	Total Current Liabilities
Non Current Liabilities Total	+ 0.97	Other Liab
Total Liab	+ 0.97	Other Liab
Total Liab	+ 0.97	Non Current Liabilities Total
Cash And Short Term Investments	+ 0.96	Total Assets
Property Plant And Equipment Gross	+ 0.96	Short Long Term Debt Total

Cash	- 0.99	Net Debt
Total Liab	- 0.9	Retained Earnings
Non Current Liabilities Total	- 0.88	Retained Earnings
Retained Earnings	- 0.88	Total Current Liabilities
Retained Earnings	- 0.87	Other Liab
Retained Earnings	- 0.84	Other Current Liab